What 3 months of Grow it Meno looked like.

We put Grow it Meno through a blinded consumer perception trial, 30 women, ages 35–55, for three months. Here's what they found.

We believe in showing our work. So when we wanted to understand how Grow it Meno performs for women navigating peri/menopause, we ran a proper trial, blinded, structured, and independently compiled. Thirty women took part over three months. No prompts, no leading questions. Just honest tracking of what they noticed.

The results were stronger than we expected, particularly around two things that matter most to this group: visible scalp and hair fall at the temples and crown. Here's what the data showed.

Eighty-four percent rating a supplement effective after a blinded trial is a number we're proud of. And the 88% who noticed changes within the first one to three months matters just as much, because we know this demographic has often been let down by products that promised the world and delivered nothing.

Here are a few of the participant's before & after pics

Hair health outcomes

• 76%Reported reduced hair shedding - with zero disagreement across the entire panel.
  
  
• 72%Saw improvement in hormonal hair loss areas - temples and crown, the zones most affected during peri/menopause.
  
  
• 52%Noticed less visible scalp - the highest-impact confidence outcome for this demographic. Only 12% saw no change.
  
  
• 40%Felt their hair was fuller overall, selecting this as a primary visual improvement alongside scalp coverage.

Wellbeing: sleep, mood & energy

Hair was the focus of the trial, but participants tracked broader wellbeing too. The results here were unexpected — and meaningful.

What participants said

We've selected a few more voices from the trial that capture the range of experience — from gradual, grounded progress to visible results that surprised even the participants themselves.